New study targets ovarian cancer in black women: could genes affect treatment?

NCT ID NCT06412120

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Researchers want to see if genetic or environmental factors affect side effects and how the drug works. About 70 women will take niraparib pills to help keep cancer from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ahmadu Bello University Teaching Hospital (ABUTH)

    RECRUITING

    Zaria, Kaduna State, Nigeria

    Contact Email: •••••@•••••

    Contact

  • Broward Health

    RECRUITING

    Fort Lauderdale, Florida, 33316, United States

    Contact Email: •••••@•••••

    Contact

  • University of Florida Jacksonville

    RECRUITING

    Jacksonville, Florida, 32209, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Miami

    RECRUITING

    Miami, Florida, 33136, United States

    Contact

    Contact